Asthma Clinical Trial
Official title:
Disclosure of Smoking in Adolescents With Asthma
This is an exploratory randomised matched cohort pilot study. It is hypothesised that adolescents (aged 13-16 years) with asthma attending a secondary care outpatient asthma clinic, will disclose their smoking status to a doctor or nurse, if questioned alone without a parent present and if advised that they will have biological validation of their smoking status using a carbon monoxide monitor. It is a study of 30 subjects, who will be recruited over a period of 6 months.
Background:
There are currently no recommendations for how to obtain accurate information on tobacco use
from teenagers aged 13-16 years, who have asthma and are attending a secondary care
outpatient clinic. The approach adopted in this study, using a simple questionnaire and
Carbon Monoxide monitor to verify smoking status, could potentially allow health care
professionals to identify at risk adolescents before they become regular smokers. It is
proposed that adolescents will disclose more accurate information about their smoking status
if questioned alone without a parent present and if advised that they will have biological
validation of their smoking status, using a carbon monoxide monitor.
The objectives of the study are:
1. Use a smoking questionnaire, which will be designed with patient and parent feedback
and contribution, to measure smoking status in adolescents, attending a secondary care
outpatient clinic.
2. To assess the appropriateness and acceptability of Carbon Monoxide(CO) monitoring to
correlate smoking status in adolescents attending a paediatric outpatient clinic.
Design and Methodology:
All patients will be selected from the paediatric asthma clinic list at Whittington Health.
The researcher will approach them with information regarding the research using a
Participant Information Sheet. The CO test and the interpretation of the results of the CO
test will be explained also. The researcher will consent both the parents and adolescents in
both groups for the study and CO test. The adolescent will need to give written informed
consent. The adolescents in group 1 (parents present) will be aware that their parents will
be able to share the information on the questionnaire, but they will assured of the
confidentiality of the CO test. This will also be explained to the parent. The adolescents
in group 2 (i.e. parents present) will be assured of the confidentiality of the
questionnaire and CO test. The confidentiality of the results will also, be explained to the
parent. The parents will consent for their child to take part in the study but the teenagers
will also be asked to assent to the study. It would be made clear to the parent that the
teenager has a choice to participate and their refusal is not necessarily related to the
fact that they may smoke. Irrespective of whether they participate or not all parents and
teenagers will have smoking advice discussed with them.
Each consenting participant will be given a short questionnaire to complete. This will
include 5-6 questions about their smoking history and how much they smoke and if they have
ever tried to give up and how. The questionnaire will also request some basic demographic
data and postcode to help identify the potential effects of environmental pollution and
passive smoking may have on the results. The questionnaire should take no longer than 5
minutes to complete.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|